OSAKA, June 13 -- Takeda Pharmaceutical, the 245-year-old Osaka-headquartered drugmaker that became Japan's largest pharmaceutical company through the 62 billion United States dollar acquisition of Shire in 2019, will cut about 4,500 jobs across its global workforce in fiscal 2026 as it executes the most aggressive restructuring program of the post-Shire era. The headline cuts, disclosed at the company's full-year 2025 earnings call, are expected to produce 170 billion yen of restructuring expenses, roughly 100 billion yen of in-year savings and more than 200 billion yen of annual savings by fiscal 2028. The package is the final major strategic move under chief executive Christophe Weber, who retires at the end of June after twelve years ...